{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-25-000004","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2025-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.074121+00:00","generated_at":"2026-05-26T03:49:41.417866+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MoonLake reports FY 2024 net loss of $121.2M, cash of $448M; advances sonelokimab to Phase 3","bullets":["Net loss for 2024 was $121.2M, compared to $44.1M in 2023, driven by increased R&D spending.","R&D expenses rose to $112.8M in 2024 from $31.8M in 2023 as Phase 3 trials for HS and PsA started.","Cash and equivalents of $448.0M as of Dec 31, 2024, down from $493.9M in Q3 2024; runway to end of 2026.","Initiated Phase 3 VELA (HS), Phase 3 IZAR (PsA), plus Phase 2 trials in PPP, axSpA, and adolescent HS.","Capital Markets Update planned for Q2 2025 to discuss Phase 3 HS data and financials."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-25-000004","json":"https://secwatch.observer/filing/0001821586-25-000004.json","markdown":"https://secwatch.observer/filing/0001821586-25-000004.md","text":"https://secwatch.observer/filing/0001821586-25-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/0001821586-25-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158625000004/mnlk-20250226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T03:49:41.417866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}